Biomedical Research Center ESPOIR POUR LA SANTE Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2016
NCT03041766
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Biomedical Research Center ESPOIR POUR LA SANTE (BRC-EPLS) | Biomedical Research Center ESPOIR POUR LA SANTE (BRC-EPLS).

Active Ingredients

Drugs in Phase 2 Trials (2)

gla-se (2 trials)

sm14 vaccine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schistosomiasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2